E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 2/23/2006 in the Prospect News Biotech Daily.

Bear Stearns cuts Schering-Plough to underperform

Schering-Plough Corp. was given an underperform rating by Bear Stearns analyst John Boris on valuation. The analyst's sum-of-the-parts analysis indicates a value of $14 per share. Bear Stearns notes risk from increasing pressure on base business and underappreciated competitive threats to the cholesterol JV, and dilution risk from an acquisition need to leverage infrastructure as primary reasons to exit the stock. Shares of the Kenilworth, N.J., pharmaceutical company were down 26 cents, or 1.35%, at $18.97 on volume of 5,905,000 shares versus the three-month running average of 7,076,790 shares. (NYSE: SGP)


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.